NCT05021913 - Safety and Performance of DKL Crosslinked Sodium Hyaluronate 23 Dermal Filler for Improvement of NLF Appearance | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 20, 2021

Primary Completion Date

January 6, 2023

Study Completion Date

January 6, 2023

Conditions

Aging, Premature

Interventions

DEVICE

DKL crosslinked sodium hyaluronate 23

is injected into the NLF on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of DKL crosslinked sodium hyaluronate 23 will be injected on Day 30; the volume of injection will not exceed 1 mL per side.

DEVICE

Juvéderm Volift™ with lidocaine (Allergan, Inc)

is injected into the NLF on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm Volift™ will be injected on Day 30; the volume of injection will not exceed 1 mL per side.

Trial Locations (1)

752 37

CTC Clinical Trial Consultants AB, Uppsala